Keyphrases
Topotecan
100%
High-risk Neuroblastoma
100%
Upfront Treatment
100%
131I-MIBG
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
42%
Newly Diagnosed
42%
Myeloablative Therapy
42%
Neuroblastoma
28%
Primary Tumor
28%
Activity Level
28%
Objective Response Rate
28%
Gigas
28%
Topoisomerase
28%
Becquerel
28%
Tumor
14%
Working Diagnosis
14%
Bone Marrow
14%
Combination Therapy
14%
Induction Treatment
14%
Stem Cells
14%
Radiosensitization
14%
Phase II Study
14%
Iodine-131 (131I)
14%
Platelets
14%
Neutrophils
14%
Administered Activity
14%
Hematologic
14%
123I-MIBG
14%
Hematotoxicity
14%
Second Course
14%
Hemoglobin
14%
Course Standards
14%
Surgery Therapy
14%
Antitumor Effect
14%
Medicine and Dentistry
Ganglioneuroblastoma
100%
(3 Iodobenzyl)guanidine I 131
100%
Topotecan
100%
Autologous Stem Cell Transplantation
42%
Neoplasm
28%
Primary Tumor
28%
Topoisomerase
28%
In Vitro
14%
Combination Therapy
14%
Iodine 131
14%
Neutrophil
14%
Radiosensitizer
14%
(3 Iodobenzyl)guanidine
14%
Platelet
14%
Peripheral Blood Stem Cell Collection
14%